Isotechnika Announces Full Enrollment Achieved in Partner Atrium's CONFIRM 1 Trial for Voclosporin Coated Coronary Stent System

    Trades on Toronto Stock Exchange - (TSX:ISA)

    EDMONTON, Jan. 22 /CNW/ - (ISA:TSX): Isotechnika Inc. announced today
that its partner, Atrium Medical Corporation has completed patient enrollment
for their CONFIRM 1, First-in-Man (FIM) drug coated coronary stent clinical
trial evaluating Atrium's CINATRATM voclosporin coated coronary stent system.
    This FIM trial is a prospective, multi-center, single blind, randomized,
controlled study using the CINATRATM voclosporin coated coronary stent system,
which will be compared to Atrium's CINATRATM bare metal coronary stent (BMS)
platform. This first use study of voclosporin on an implantable medical device
enrolled 100 patients and is currently being conducted at seven hospitals in
Belgium with Glenn Van Langenhove, MD, PhD of Middelheim Hospital, Antwerp, as
the study's Principal Investigator. The primary endpoint of the trial is to
evaluate the safety and performance of the CINATRATM voclosporin coated
coronary stent system in patients with de novo coronary artery disease.
Patient outcomes, in addition to drug coated stent performance, will be
assessed by measuring Late Lumen Loss, in-stent and in-segment lumen loss
measurements at six months following implantation.
    "We are extremely pleased to have completed enrollment within our
projected timelines," said Trevor Carlton, Atrium's President. "Our last
patient is expected to have their six month follow-up procedure at the end of
June 2009 with results available in the third quarter of this year."
    "The progress that Atrium has been able to achieve in such a short period
of time is extremely exciting," stated Dr. Robert Foster, Isotechnika's Chief
Executive Officer. "We look forward to sharing the results with both the
scientific and investment communities later this year."

    About CINATRA(TM) Voclosporin Coated Coronary Stent System

    The CINATRA(TM) Voclosporin Coated Coronary Stent System is comprised of
a cobalt chromium bare metal stent mounted on a delivery balloon catheter. The
stent and the balloon are coated with Atrium's proprietary Omega-3 fatty acid
coating technology utilizing voclosporin for its anti-inflammatory properties.

    About Isotechnika

    Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential will exceed $4 billion annually in sales
for calcineurin inhibitors by 2010.
    Voclosporin is a next generation calcineurin inhibitor, which recently
completed a Phase 2b North American trial for the prevention of kidney
rejection following transplantation. An extension to the Phase 2b trial and a
combined Phase 3 European/Canadian trial for the treatment of moderate to
severe psoriasis are ongoing. Our partner, Lux Biosciences, is currently
conducting three separate Phase 2/3 pivotal trials investigating voclosporin
(referred to as LUVENIQTM by Lux) for the treatment of uveitis. Voclosporin
has also entered First-in-Man trials as the drug utilized in the CINATRA(TM)
Drug Coated Coronary Stent system developed by our partner, Atrium Medical
    Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
at or

    Forward-Looking Statements

    This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements.

For further information:

For further information: Robert Foster, CEO, Isotechnika Inc., Phone:
(780) 487-1600 (x247), Fax: (780) 484-4105,;
Stephanie Gillis-Paulgaard, Director, Communications, Isotechnika Inc., Phone:
(780) 909-4661, Fax: (780) 484-4105, E-mail:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890